| Vol. 11.48 – 18 December, 2020 |
| |
|
|
| Direct targeted heat shock factor 1 (HSF1) inhibitor robustly inhibited the HSF1 cancer gene signature and prostate cancer cell proliferation. It potently attenuated tumor progression in four therapy-resistant prostate cancer animal models, including an neuroendocrine prostate cancer model, where it caused profound tumor regression. [Science Translational Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Hyperactive mutation of PI3K-AKT-mTOR signaling protected cancer cells from oxidative stress and ferroptotic death through SREBP1/SCD1-mediated lipogenesis, and combination of mTORC1 inhibition with ferroptosis induction showed therapeutic promise in preclinical models. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists indicate that MUC1-C promotes neuroendocrine prostate cancer progression by integrating activation of E2F1 and esBAF with induction of NOTCH1, NANOG, and stemness. [Cancer Research] |
|
|
|
| SPOP’s degradation stabilized AR, ARv7 and c-Myc, promoting oncogenicity. Phospho-resistant SPOP completely suppressed tumorigenesis in vivo, indicating that LIMK2-mediated SPOP degradation is a key event in prostate cancer progression. [British Journal of Cancer] |
|
|
|
| To validate the specificity of an in-house developed IHC assay as well as to validate the correlation between schlafen 11 (SLFN11) and the response to different DNA-damaging agents and DNA damage-response inhibitors, SLFN11 knockout cells were generated in DU145 prostate cancer cells using CRISPR/Cas9. [British Journal of Cancer] |
|
|
|
| Overexpression of G2 and S phase-expressed-1 (GTSE1) promoted proliferation in LNCaP cells, whereas silencing GTSE1 inhibited the growth of C4-2 cells. [Laboratory Investigation] |
|
|
|
| Using single-cell RNA sequencing analysis, researchers found that Olfactomedin 4 (OLFM4) was expressed in multiple stem/progenitor-like cell populations in both the normal prostate epithelium and RWPE1 cells and was frequently co-expressed with KRT13 and LY6D in RWPE1 cells. [Scientific Reports] |
|
|
|
|
| The authors summarize the manifestations of inter-tumoral and intra-tumoral heterogeneity in primary and metastatic prostate cancer. They emphasize the significant contribution of genomics studies in the field and discuss the importance of phenotypic changes. [Nature Reviews Urology] |
|
|
|
|
| Tabula Rasa HealthCare, Inc. (TRHC) announced it has entered into a partnership with Physiomics plc, the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. Initially, they will focus on the drug docetaxel, which is commonly used to treat prostate, breast and other cancers. [Tabula Rasa HealthCareâ„¢] |
|
|
|
| Arvinas, Inc. announced clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. For ARV-110, the ongoing dose escalation portion of the Phase I/II trial in men with metastatic castration-resistant prostate cancer has provided additional evidence of anti-tumor activity and patient benefit, including a prostate specific antigen reduction of more than 50% rate of 40% in a molecularly defined patient population. [Arvinas, Inc.] |
|
|
|
|
| January 7 – 8, 2021 Virtual |
|
|
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| Scripps Research Institute – La Jolla, California, United States |
|
|
|
| Pfizer – La Jolla, California, United States |
|
|
|
| University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
|